Expansion of major histocompatibility complex-restricted antimelanoma cytotoxic T-cell lymphocyte clones with identical T-cell receptor from tumor-infiltrating lymphocytes. 1992

M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.

Tumor-infiltrating lymphocytes (TILs) were isolated from a subcutaneous metastasis of melanoma and cytotoxic T-cell lymphocyte (CTL) lines were obtained by sensitizing in vitro four separate aliquots of TILs with autologous tumor cells and recombinant interleukin-2. All CTL lines were predominantly WT31+, CD3+, and CD8+ and displayed a preferential cytotoxic activity against the autologous tumor. T-cell receptor (TCR) composition was analyzed by using the polymerase chain reaction with 5' variable region (V alpha or V beta)-specific primers and 3' constant (C alpha or C beta) primers. The entire repertoire of the V alpha and V beta gene families tested was present in fresh TILs and in the CTL lines, although, in the latter, consistent quantitative variations in transcripts of several V alpha and V beta occurred. CTL clones that exhibited CD3-dependent and major histocompatibility complex-restricted killing of the autologous melanoma were isolated from the four TIL cultures. TCR analysis indicated that, independently from the culture of origin, only two combinations of V alpha and V beta gene families were present in the majority of these CTL clones. These V alpha and V beta gene families were not found in a panel of CTL clones that did not lyse the autologous tumor. This study indicates that recognition of melanoma antigens can strongly select for certain types of TCR-bearing T-lymphocytes.

UI MeSH Term Description Entries
D008285 Major Histocompatibility Complex The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement. Histocompatibility Complex,Complex, Histocompatibility,Complex, Major Histocompatibility,Complices, Histocompatibility,Complices, Major Histocompatibility,Histocompatibility Complex, Major,Histocompatibility Complices,Histocompatibility Complices, Major,Major Histocompatibility Complices
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015332 Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors. T-Cell Antigen Receptor alpha-Chain Gene Rearrangement,T-Lymphocyte Antigen Receptor alpha-Chain Gene Rearrangement,Gene Rearrangement, alpha-Chain T Cell Antigen Receptor,T Cell alpha-Chain Gene Rearrangement,T Lymphocyte alpha-Chain Gene Rearrangement,Gene Rearrangement, alpha Chain T Cell Antigen Receptor,T Cell Antigen Receptor alpha Chain Gene Rearrangement,T Cell alpha Chain Gene Rearrangement,T Lymphocyte Antigen Receptor alpha Chain Gene Rearrangement,T Lymphocyte alpha Chain Gene Rearrangement
D015333 Gene Rearrangement, beta-Chain T-Cell Antigen Receptor Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors. T-Cell Antigen Receptor beta-Chain Gene Rearrangement,T-Lymphocyte Antigen Receptor beta-Chain Gene Rearrangement,Gene Rearrangement, beta-Chain T Cell Antigen Receptor,T Cell beta-Chain Gene Rearrangement,T Lymphocyte beta-Chain Gene Rearrangement,Gene Rearrangement, beta Chain T Cell Antigen Receptor,T Cell Antigen Receptor beta Chain Gene Rearrangement,T Cell beta Chain Gene Rearrangement,T Lymphocyte Antigen Receptor beta Chain Gene Rearrangement,T Lymphocyte beta Chain Gene Rearrangement

Related Publications

M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
June 1981, The Journal of experimental medicine,
M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
October 1996, International journal of cancer,
M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
December 1997, Japanese journal of cancer research : Gann,
M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
July 1994, Transplantation,
M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
July 1995, Annals of the New York Academy of Sciences,
M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
January 2001, Journal of immunotherapy (Hagerstown, Md. : 1997),
M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
June 1993, The Journal of experimental medicine,
M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
February 1997, Japanese journal of cancer research : Gann,
M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
October 1990, European journal of immunology,
M Sensi, and C Castelli, and S Salvi, and A Mazzocchi, and R Mortarini, and G Nicolini, and A Anichini, and G Parmiani
June 1995, The Journal of experimental medicine,
Copied contents to your clipboard!